A daily dose of Relay Therapeutics’ experimental drug for cholangiocarcinoma, a rare cancer of the bile ducts, led to tumor shrinkage of a third or more in 15 of 17 patients with metastatic disease, the company said Wednesday.
The results were released in an abstract at the annual meeting of the European Society for Molecular Oncology, where they will be released in full on Sunday.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.